Brightcove Launches AI Content Suite, The First General Availability Release From Its Successful AI Pilot Program, To Maximize Content Creation and Production for Customers
Brightcove (NASDAQ: BCOV), the world’s most trusted intelligent video engagement platform company, announces the launch of its AI Content Suite, the company's first official general availability release following a successful customer pilot program in 2024. This innovative suite introduces a range of AI-powered tools to increase the impact of video content while also improving business productivity, making it a seamless and easy experience for content creators to get more from their content and drive greater engagement across their audiences.
The Brightcove AI Content Suite includes three AI-powered capabilities – content creation, metadata optimization, and translation – which simplify video content production by automating the creation and optimization processes.
"The AI Content Suite is a force multiplier for anyone looking to expand the impact of their video content without increasing their workload," said Scott Levine, Chief Product Officer at Brightcove. "Embedded within our video platform, the AI Content Suite easily and quickly enables a video creation multiplier effect without going to other tools and platforms. This allows our customers to maximize their content reach and engagement."
The AI Content Suite allows companies to harness the full potential of the video content they own with features including:
- Rapid, automated conversion of long-form content into engaging short-form clips, highlight reels, and theme-based chapters to maximize reach across channels
- Conversion of horizontal video content into vertical formats to extend engagement with mobile viewers and across social platforms
- Enhanced discoverability through auto-generated metadata (including titles, tags and descriptions), ensuring audiences find and engage with relevant content
- Universal translation capabilities to dozens of languages to extend global reach and make content more accessible (coming soon)
The Brightcove AI Content Suite is part of Brightcove’s broader AI product strategy and roadmap. It was built in close collaboration with customers across various industries to create solutions that address their business needs, such as deepening audience engagement and improving efficiencies in creating, editing and distributing video content.
"The AI Content Suite transformed our clip and trailer production process. What used to take hours now takes minutes, allowing us to reduce costs and focus more on creativity and strategy,” shared Remi Brunier, Director of Product and UX at STV, the most-watched peak-time channel in Scotland and home to some of the most popular shows on Scottish television. STV was one of the dozens of customers who participated in Brightcove’s AI pilot program. “By automating the creation of engaging, concise trailers for our content, we've scaled our production for a wider range of titles and significantly reduced costs. This shift has been critical for our business, allowing our team to focus on high-profile projects and enhance our presence on social media platforms.”
The Brightcove AI Suite will continue to launch new products based on customer feedback. These include the addition of text-to-video capabilities and AI-powered automated video interactivity, personalization, and recommendations to engage audiences and build loyalty.
Brightcove is committed to maintaining the highest security standards and ethical AI use. It ensures all tools in the AI Content Suite are backed by its robust security framework and the Brightcove AI Pledge. As part of this pledge, Brightcove will never use customers’ content or personal data to train AI models without their explicit consent.
For more information, visit Brightcove.com.
About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X, Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129442732/en/
Contacts
Media Contacts:
Brightcove
press@brightcove.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom